Cantor Fitzgerald Brokers Reduce Earnings Estimates for BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities researchers at Cantor Fitzgerald cut their FY2026 earnings estimates for BioCryst Pharmaceuticals in a research note issued to investors on Wednesday, October 15th. Cantor Fitzgerald analyst S. Seedhouse now expects that the biotechnology company will earn $0.01 per share for the year, down from their previous estimate of $0.45. Cantor Fitzgerald currently has a “Overweight” rating and a $26.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. The firm’s revenue for the quarter was up 49.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.06) earnings per share.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. TD Cowen started coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday. They set a “buy” rating and a $30.00 price target on the stock. Bank of America increased their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, July 1st. Finally, Evercore ISI reiterated an “in-line” rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.18.

BioCryst Pharmaceuticals Trading Down 1.3%

BCRX stock opened at $6.63 on Friday. The company’s 50 day moving average is $7.84 and its 200 day moving average is $8.64. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -36.83, a price-to-earnings-growth ratio of 0.78 and a beta of 1.05. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31.

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $32,000. GAMMA Investing LLC boosted its stake in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,449 shares during the period. Family Legacy Financial Solutions LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $72,000. New Age Alpha Advisors LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $62,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $79,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. This represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.10% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.